Evidence map›Paper›PMID 25324681›Full record

ArticleMolecular vision2014

ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes.

Tingting Li, Jianyan Hu, Shanshan Du, Yongdong Chen, Shuai Wang, Qiang Wu

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. RAAS in diabetic retinopathy: mechanisms and therapies.Archives of endocrinology and metabolism · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Cellular targets in diabetic retinopathy therapy.World journal of diabetes · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tingting LiDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Jianyan HuDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Shanshan DuDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Yongdong ChenDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Shuai WangDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Qiang WuDepartment of Ophthalmology, the Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China ; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.
Shanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRetinal vascular dysfunction caused by vascular endothelial growth factor (VEGF) is the major pathological change that occurs in diabetic retinopathy (DR). It has recently been demonstrated that G protein-coupled receptor 91 (GPR91) plays a major role in both vasculature development and retinal angiogenesis. In this study, we examined the signaling pathways involved in GPR91-dependent VEGF release during the early stages of retinal vascular change in streptozotocin-induced diabetes.

methodsDiabetic rats were assigned randomly to receive intravitreal injections of shRNA lentiviral particles targeting GPR91 (LV.shGPR91) or control particles (LV.shScrambled). Accumulation of succinate was assessed by gas chromatography-mass spectrometry (GC-MS). At 14 weeks, the ultrastructure and function of the retinal vessels of diabetic retinas with or without shRNA treatment were assessed using hematoxylin and eosin (HE) staining, transmission electron microscopy (TEM), and Evans blue dye permeability. The expression of GPR91, extracellular signal-regulated kinases 1 and 2 (ERK1/2) and cyclooxygenase-2 (COX-2) were measured using immunofluorescence and western blotting. COX-2 and VEGF mRNA were determined by quantitative RT-PCR. Prostaglandin E2 (PGE2) and VEGF secretion were detected using an enzyme-linked immunosorbent assay.

resultsSuccinate exhibited abundant accumulation in diabetic rat retinas. The retinal telangiectatic vessels, basement membrane thickness, and Evans blue dye permeability were attenuated by treatment with GPR91 shRNA. In diabetic rats, knockdown of GPR91 inhibited the activities of ERK1/2 and COX-2 as well as the expression of PGE2 and VEGF. Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398.

conclusionsOur data suggest that hyperglycemia causes succinate accumulation and GPR91 activity in retinal ganglion cells, which mediate VEGF-induced retinal vascular change via the ERK1/2/COX-2/PGE2 pathway. This study highlights the signaling pathway as a potential target for intervention in DR.

Indexed as

MAP Kinase Signaling SystemAnimalsCyclooxygenase 2Diabetes Mellitus, ExperimentalDiabetic RetinopathyDinoprostoneMaleRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledRetinal Ganglion CellsRNA, MessengerRNA, Small InterferingSuccinic AcidVascular Endothelial Growth Factor ACyclooxygenase 2DinoprostonePtgs2 protein, ratReceptors, G-Protein-CoupledRNA, MessengerRNA, Small InterferingSuccinic AcidSucnr1 protein, ratVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat

Identifiers

PMID25324681
PMCPMC4119234
OpenAlexW2163150716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.